Savara Inc.: Well-funded orphan lung disease company with four clinical studies in late-stage pipeline. The two Phase 3 studies include 1) IMPALA: Molgradex (inhaled GM-CSF) for autoimmune pulmonary alveolar proteinosis (aPAP), and 2) AVAIL: AeroVanc (inhaled vancomycin) for MRSA lung infection in CF. The two studies in Phase 2 development are both investigating Molgradex for the treatment of NTM lung infection. OPTIMA is in non-CF patients and ENCORE is in CF patients. In June 2019, topline results from IMPALA were announced. While the study did not achieve statistical significance on the primary endpoint, the totality of the efficacy data are encouraging and adverse event frequencies were similar between the treatment arms and placebo. The company was granted a Type C meeting with the FDA and recently received a written response from the agency indicating the briefing package did not provide sufficient evidence of efficacy and safety. The company is evaluating the feedback from the FDA to determine the best path forward, which may include another Phase 3 trial. Savara still anticipates filing for Breakthrough Designation in the US.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase III
Disease Space
Fibrosis, Rare Disease, Respiratory
Finance
Pre-Revenues
Industry
Biotechnology, Life Sciences
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Profiles:
Address:
6836 Bee Cave Road
Building 3, Suite 200
Austin, TX 78746
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Savara, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Bain Capital Life Sciences Investors LLC 12.45 5,128,593 11.18 13F 2020-03-31
Farallon Capital Management LLC 11.71 4,825,086 10.52 13F 2020-03-31
Ecor1 Capital LLC 3.48 1,432,664 3.12 13F 2020-03-31
The Vanguard Group, Inc. 3.34 1,377,674 3.00 Funds 2020-05-31
AXA Investment Managers UK Ltd. 3.26 1,340,996 2.92 13F 2020-03-31
Vanguard Group, Inc. (Subfiler) 3.16 1,302,976 2.84 13F 2020-03-31
BlackRock Fund Advisors 2.89 1,190,837 2.60 13F 2020-03-31
BlackRock Institutional Trust Co. NA 2.20 908,243 1.98 13F 2020-03-31
Point72 Asset Management LP (Old) 2.20 907,464 1.98 13F 2020-03-31
Goldman Sachs & Co. LLC 2.00 824,829 1.80 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.